<DOC>
	<DOC>NCT00739973</DOC>
	<brief_summary>Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>msDBP ≥ 90 mmHg and &lt; 110 mmHg at the visit prior to Visit 3 (Visit 2 or optional Visit 201) msDBP ≥ 95 mmHg and &lt; 110 mmHg at Visit 3 (Day 1 / randomization). All patients must have an absolute difference of ≤ 10 mmHg in their msDBP during the last 2 visits of the singleblind runin period (Visit 2 and 3 or Visits 201 and 3). Severe hypertension Pregnant or nursing (lactating) women Women of childbearing potential Previous or current diagnosis of heart failure (NYHA Class IIIV). Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1. Uncontrolled Type 1 or Type 2 diabetes mellitus Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures History of malignancy within 5 years History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hypertension, Aliskiren, Amlodipine</keyword>
</DOC>